TIBSOVO (ivosidenib) is an inhibitor of isocitrate dehydrogenase 1 (IDH1) enzyme. TIBSOVO (ivosidenib) is available as a film-coated 250 mg tablet for oral administration. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet coating includes FD&C blue #2, hypromellose, lactose monohydrate, titanium dioxide, and triacetin.
TIBSOVO (ivosidenib) - Tablet 250 mg
The recommended dosage is 500 mg orally once daily with or without food until disease progression or unacceptable toxicity.
Acute Myeloid Leukemia (AML)
• Newly diagnosed AML who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
• Relapsed or refractory AML.
Locally Advanced or Metastatic Cholangiocarcinoma
• Locally advanced or metastatic cholangiocarcinoma who have been previously treated
